Weir MR, Bhaduri S, Lee K, Galvez O, et al. Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria. Kidney Int 2026 Sep 23:S0085-2538(26)00808-2. doi: 10.1016/j.kint.2026.
PMID: 42778148